Evidence map›Paper›PMID 41587966›Full record

ArticleNature communications2026

Discovery of NIRF theranostic probes targeting amyloid-β and cholinesterases in Alzheimer's disease models.

Himanshu Rai, Rishabh Singh, Gauri Shankar, Sanskriti Rai, Prabhat Kumar, Aishwarya S Nilakhe, Neha Singh, Poonam Bhadoria, Gourav Singh, Venkatnarayan Ramanathan and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Himanshu RaiDepartment of Pharmaceutical Engineering & Technology, Indian Institute of Technology (BHU), Varanasi, Uttar Pradesh, India.ORCID http://orcid.org/0000-0002-5615-5058
Rishabh SinghDepartment of Biophysics, All India Institute of Medical Sciences, New Delhi, India.ORCID http://orcid.org/0000-0003-4245-8055
Gauri ShankarDepartment of Pharmaceutical Engineering & Technology, Indian Institute of Technology (BHU), Varanasi, Uttar Pradesh, India.
Sanskriti RaiDepartment of Biophysics, All India Institute of Medical Sciences, New Delhi, India.ORCID http://orcid.org/0009-0005-0001-7210
Prabhat KumarDepartment of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi, India.ORCID http://orcid.org/0009-0006-6257-9830
Aishwarya S NilakheNational Institute of Immunology, New Delhi, India.
Neha SinghDepartment of Pharmaceutical Engineering & Technology, Indian Institute of Technology (BHU), Varanasi, Uttar Pradesh, India.ORCID http://orcid.org/0000-0003-4389-6284
Poonam BhadoriaDepartment of Chemistry, Indian Institute of Technology (BHU), Varanasi, Uttar Pradesh, India.ORCID http://orcid.org/0009-0007-6318-9268
Gourav SinghDepartment of Pharmaceutical Engineering & Technology, Indian Institute of Technology (BHU), Varanasi, Uttar Pradesh, India.ORCID http://orcid.org/0000-0002-8234-9489
Venkatnarayan RamanathanDepartment of Chemistry, Indian Institute of Technology (BHU), Varanasi, Uttar Pradesh, India.
Sarika GuptaNational Institute of Immunology, New Delhi, India.ORCID http://orcid.org/0000-0002-3054-0337
Sairam KrishnamurthyDepartment of Pharmaceutical Engineering & Technology, Indian Institute of Technology (BHU), Varanasi, Uttar Pradesh, India.
Saripella SrikrishnaDepartment of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi, India.ORCID http://orcid.org/0000-0002-6019-1588
Saroj KumarDepartment of Biophysics, All India Institute of Medical Sciences, New Delhi, India.ORCID http://orcid.org/0000-0001-7029-1163
Gyan ModiDepartment of Pharmaceutical Engineering & Technology, Indian Institute of Technology (BHU), Varanasi, Uttar Pradesh, India. gpmodi.phe@itbhu.ac.in.ORCID http://orcid.org/0000-0002-8003-5566

Funding

DST | Science and Engineering Research Board (SERB) Under CRG scheme; File No. CRG/2022/007126/BHS)Indian Council of Medical Research (ICMR) Project ID: 2021-9522/F1; File No. 3/1/2/170/Neuro/2021-NCD-I
6 · The paper itself

Abstract

Alzheimer's disease (AD) remains a major unmet medical challenge, with limited tools that integrate early diagnosis and therapeutic intervention. Considering the pivotal roles of amyloid-β (Aβ) and cholinesterases (ChEs) in AD etiology, we report dual-functional theranostic NIR-I probes. The lead candidate, I-43, exhibits favorable NIR optical properties (Stokes shift ≥ 220 nm) and binds strongly to Aβ fibrils, with K

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesCholinesterasesTheranostic NanomedicineAnimalsBrainCholinesterase InhibitorsDisease Models, AnimalFemaleFluorescent Chemosensor CompoundsFluorescent DyesHumansMaleMiceMice, TransgenicPeptide FragmentsAmyloid beta-PeptidesCholinesterase InhibitorsCholinesterasesFluorescent Chemosensor CompoundsFluorescent DyesPeptide Fragments

Identifiers

PMID41587966
PMCPMC12915651

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.